866-997-4948(US-Canada Toll Free)

Francisella Tularensis Infections - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : May 2013

Category :

Oncology

No. of Pages : 43 Pages


Global Markets Directs, \'Francisella Tularensis Infections Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Francisella Tularensis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections. 

Francisella Tularensis Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Francisella Tularensis Infections.
  • A review of the Francisella Tularensis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Francisella Tularensis Infections pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Francisella Tularensis Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Francisella Tularensis Infections pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Francisella Tularensis Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Francisella Tularensis Infections 7
Francisella Tularensis Infections Therapeutics under Development by Companies 9
Francisella Tularensis Infections Therapeutics under Investigation by Universities/Institutes 10
Pre-Clinical Stage Products 11
Comparative Analysis 11
Francisella Tularensis Infections Therapeutics - Products under Development by Companies 12
Francisella Tularensis Infections Therapeutics - Products under Investigation by Universities/Institutes 13
Companies Involved in Francisella Tularensis Infections Therapeutics Development 14
Aduro BioTech 14
Affinium Pharmaceuticals, Inc. 15
DiaMedica Inc. 16
Achaogen Inc. 17
Evolva SA 18
EpiVax, Inc. 19
Tetraphase Pharmaceuticals Inc. 20
Francisella Tularensis Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
EV-009 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
TuliVax - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Fabl Inhibitor Program - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TP-271 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Lm-Tularemia - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
EV-035 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ACHN-978 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Enoyl Reductase Inhibitors - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Recombinant Tularemia Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Francisella Tularensis Infections Therapeutics - Drug Profile Updates 35
Francisella Tularensis Infections Therapeutics - Discontinued Products 36
Francisella Tularensis Infections Therapeutics - Dormant Products 37
Francisella Tularensis Infections - Product Development Milestones 38
Featured News & Press Releases 38
Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271 38
Sep 13, 2011: Aduro BioTech Receives Three SBIR Grants To Develop Therapeutic Vaccines 38
Aug 30, 2010: Achaogen Receives $64 Million Contract From BARDA For Development Of ACHN-490 39
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 39
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 40

Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Table


Number of Products Under Development for Francisella Tularensis Infections, H1 2013 7
Products under Development for Francisella Tularensis Infections - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 13
Aduro BioTech, H1 2013 14
Affinium Pharmaceuticals, Inc., H1 2013 15
DiaMedica Inc., H1 2013 16
Achaogen Inc., H1 2013 17
Evolva SA, H1 2013 18
EpiVax, Inc., H1 2013 19
Tetraphase Pharmaceuticals Inc., H1 2013 20
Assessment by Monotherapy Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Francisella Tularensis Infections Therapeutics - Drug Profile Updates 35
Francisella Tularensis Infections Therapeutics - Discontinued Products 36
Francisella Tularensis Infections Therapeutics - Dormant Products 37

List of Chart


Number of Products under Development for Francisella Tularensis Infections, H1 2013 7
Products under Development for Francisella Tularensis Infections - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *